Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Related REGN
UPDATE: Regeneron, Sanofi Report Commencement of Phase 3 Study Of Dupilumab In Patients With AD
TGIF As Markets Rally; S&P 500 Posts Longest Weekly Loss Streak Since 2011
Related AGN
Report: Actavis, Sanofi To Bid On Over-The-Counter Drug Maker
IBM's Report Weighs On The Dow, Apple Helps Boost The Nasdaq, S&P 500 Extends Winning Streak
Deal Frenzy: 2014 Sees Record M&A Volume (Fox Business)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Oct 2014Guggenheim SecuritiesInitiates Coverage onBuy
Sep 2014Credit SuisseMaintainsOutperform
Sep 2014Brean CapitalMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters